N-(4-氟-3-碘苄基)胍 | 159719-55-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-氟-3-碘苄基)胍
• 英文名称: (4-fluoro-3-iodobenzyl)guanidine
• 英文别名: 1-(4-Fluoro-3-iodobenzyl)guanidine；2-[(4-fluoro-3-iodophenyl)methyl]guanidine
• CAS: 159719-55-8
• 化学式: C₈H₉FIN₃
• 分子量: 293.082
• InChiKey: IKWJWCZWJVPPIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  氰胺 、 4-fluoro-3-iodobenzylamine hydrochloride 反应 4.0h， 生成 N-(4-氟-3-碘苄基)胍
  参考文献：
  名称：

  (4-[18F]Fluoro-3-iodobenzyl)guanidine, a Potential MIBG Analog for Positron Emission Tomography

  摘要：

  The aims of this investigation were to develop a no-carrier-added (nea) synthesis of (4-[F-18]-fluoro-3-iodobenzyl)guanidine (F-18]FIBG) and to evaluate its potential as an MIBG analogue useful for positron emission tomography. [F-18]FIBG was prepared in four steps starting from 4-cyano-2-iodo-N,N,N-trimethylanilinium trifluoromethanesulfonate in 5% decay-corrected radiochemical yield in a total synthesis time of 130 min. The specific activity was more than 1500 Ci per mmol. In vitro binding studies showed that the percent binding of [F-18]FIBG to SK-N-SH human neuroblastoma cells remained constant over a 3-log activity range and was similar to that of nca [I-131]MIBG. Specific and high uptake of FIBG was also seen in mouse heart and adrenals. The in vitro and in vivo properties of[F-18]FIBG suggest that this compound may be a useful positron-emitting analogue of MIBG.

  DOI：

  10.1021/jm00047a022

文献信息

• COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
  申请人：Lantheus Medical Imaging, Inc.

  公开号：EP3567029A1

  公开（公告）日：2019-11-13

  The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

  本发明涉及合成和使用成像剂或其前体的系统、组合物和方法。成像剂前体可通过本文所述方法转化为成像剂。在某些情况下，成像剂富含 18F。在某些情况下，成像剂可用于成像受试者感兴趣的区域，包括但不限于心脏、心血管系统、心脏血管、大脑和其他器官。在一些实施方案中，提供了用于评估受试者部分灌注和神经支配失配的方法和组合物。
• NEURONAL IMAGING AND TREATMENT
  申请人：Tylerton International Holdings Inc.

  公开号：EP2948188B1

  公开（公告）日：2021-09-08
• US9550000B2
  申请人：——

  公开号：US9550000B2

  公开（公告）日：2017-01-24
• [EN] LIGANDS FOR IMAGING CARDIAC INNERVATION<br/>[FR] LIGANDS POUR IMAGERIE D'INNERVATION CARDIAQUE
  申请人：BRISTOL MYERS SQUIBB PHARMA CO

  公开号：WO2008083056A2

  公开（公告）日：2008-07-10

  [EN] Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with ¹⁸F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.
  [FR] L'invention concerne de nouveaux composés s'utilisant comme agents d'imagerie dans le cadre d'applications de médecine nucléaire (imagerie PET) pour effctuer l'imagerie de l'innervation cardiaque. Ces radiotraceurs fondés sur la PET peuvent manifester une stabilité accrue, une diminution de la libération de NE (ce qui contribue à réduire les effets secondaires), de meilleures données quantitatives et/ou une affinité élevée pour le VMAT par rapport aux radiotraceurs antérieurs. L'invention concerne également des méthodes pour utiliser ces composés pour effectuer l'imagerie de l'innervation cardiaque. Dans certains cas, les composés sont obtenus par dérivation de certains composés marqués par ^{1 8}F
• [EN] COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS<br/>[FR] COMPOSITIONS, PROCÉDÉS ET SYSTÈMES DE SYNTHÈSE ET D'UTILISATION D'AGENTS D'IMAGERIE
  申请人：LANTHEUS MEDICAL IMAGING INC

  公开号：WO2013036869A2

  公开（公告）日：2013-03-14

  The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.